Drug Type Antibody drug conjugate (ADC) |
Synonyms MYX 2449, MYX-2449 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), NMT1 inhibitors(N-myristoyltransferase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | GB | Myricx Pharma Ltd.Startup | 18 Apr 2023 |
Stomach Cancer | Preclinical | GB | Myricx Pharma Ltd.Startup | 18 Apr 2023 |